NASHNET

NASHNET is a global network of thought leaders dedicated to innovating nonalcoholic steatohepatitis (NASH) care delivery.

[NASHNET @NASHNETglobal]

To celebrate International #NASHDay, we are proud to present a white paper covering the role of biomarkers in identifying #NASH

Thanks to the Task Force for leading this important work and Novo Nordisk for supporting

Access here:
https://t.co/wn0v4rrERa

#StepUpForNASH

[NASHNET @NASHNETglobal]

@NoureddinMD describes the importance of cost-effectiveness studies in regulatory decision making. Excellent insights! #livertwitter #NAFLD #NASH

[SurfingMASH @surfing_MASH]

S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market

https://t.co/veqA6s1fbE

The final conversation of Episode 16 explores possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents.

[NASHNET @NASHNETglobal]

Excited to see NASHNET Advisor @schattenbergJ featured in this podcast discussing innovations in NASH patient identification

[SurfingMASH @surfing_MASH]

S2-E20 - 14-variable Machine Learning Model Identifies Probable NASH Patients From Electronic Health Records

https://t.co/zmuIUs1sBM

Jörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings.

[Naim Alkhouri @AlkhouriNaim]

My favorite slide so far @CLDFoundation #LiverConnect . The one and only @NoureddinMD showing how to think about non-invasive tests for fatty liver. @AASLDtweets @NASH_and_coffee @surfing_NASH @NASHNETglobal @Education_Nash @nashbiotechs

[AASLD @AASLDtweets]

Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Will be held Wednesday, May 19 at 11 am.

Register Now: https://t.co/3ohL8fVuVf

[NASHNET @NASHNETglobal]

@DrMTLong on #ProviderEducation during COVID in the Q1 NASH Trend Alerts #podcast

Listen to the full episode on our website --> https://t.co/42vZUTgUAb

#NASH #NAFLD #livertwitter

[NASHNET @NASHNETglobal]

Listen on the NASHNET website: https://t.co/42vZUTgUAb

Or search "NASHNET" in Apple Podcasts, Spotify, or Google Podcasts.

[MountSinaiLiver @MountSinaiLiver]

@MountSinaiNYC @IcahnMountSinai @MountSinaiLiver Faculty Amreen Dinani featured on NASHNET #podcast! Impact of #COVID19 on #NAFLD/#NASH care delivery, emerging trends, Innovative provider #education initiatives #livertwitter 👉👉👉https://t.co/4YDk6wM3El

[NASHNET @NASHNETglobal]

We're excited to announce the release of the Q1 2021 NASH Trend Alerts podcast episode featuring @DrMTLong and Dr. Amreen Dinani. Listen to the episode on the NASHNET website: https://t.co/42vZUTgUAb

@The_BMC @MountSinaiLiver #livertwitter #NAFLD
#NASH #podcast

[NASHNET @NASHNETglobal]

Thank you to our Advisors for making the publication of the novel Cost-Utility Analysis in @AGA_Gastro a huge success! Read more about future implications of the findings on our blog: https://t.co/CTUMvqAA37

@NoureddinMD @AlkhouriNaim @GeorgeT400 @fviviana83 @NGirgrah

[NASHNET @NASHNETglobal]

Recent findings published in @AGA_Gastro indicate that screening for #NAFLD in patients with #T2D with US followed by VCTE is cost effective (as compared to no screening). Read the full analysis here: https://t.co/Utgnsioatl

[Echosens @Echosens]

Battling the impact of NAFLD by screening people for fibrosis with non-invasive tests, such as #FibroScan, is cost-effective. #LiverHealthMatters @NASHNETglobal
Read our blog on this topic https://t.co/cl3VyBCvNi

[Naim Alkhouri @AlkhouriNaim]

So happy to be part of this free Liver Screening event. New data support the cost-effectiveness of screening all diabetics for NAFLD. #NAFLD @NASHNETglobal @NASH_Education @NoureddinMD @anitakohli

[Mazen Noureddin, MD, MHSc @NoureddinMD]

Thanks to @NASHNETglobal collaboration, @MountSinaiLiver, McCann economical firm for the work in the last 1.5 year. Thanks to @KathleenCoreyMD and #ZobairYouonossi for enriching the literature that we used.

[American Liver Foundation National @liverUSA]

Today is Int'l #NASHDay! What's #NASH? It stands for Non-alcoholic Steatohepatitis & it's the severe form of #NAFLD. Visit our NASH Resource Center to learn more about the disease that's rapidly become one of the top causes for liver transplant in the US: https://t.co/SUkqvN4Se0!

[Global Liver Institute @GlobalLiver]

Thank you to all the organizations, from 6 continents, and to our panelists and patients worldwide, for joining us on International #NASHday. Together, we are a powerful and passionate global force to tackle #NASH.

@AASLDtweets @EASLedu @EASLnews @WHO @EU_Health @ncdalliance

[Global Liver Institute @GlobalLiver]

We are proud to share our most recent GLI press release. #NASHday

@AASLDtweets @EASLedu @EASLnews @WHO_Europe @WHO

https://t.co/Fee79g6XTG

[NASHNET @NASHNETglobal]

In Episode #2 of the NASHNET podcast series, Dr. Fuchs highlights the importance of NASH awareness and stakeholder buy-in. Listen to the full episode at https://t.co/fEM8gVX0uI @RichmondVAMC

[NASHNET @NASHNETglobal]

Dr. Dinani from @MountSinaiNYC advocates for increased NASH awareness and provider education to improve NASH care pathways. Listen to Episode #2 of our educational podcast series at https://t.co/fEM8gVX0uI

[NASHNET @NASHNETglobal]

In Episode #2 of our educational podcast series, Dr. Fuchs and Dr. Dinani discuss NASH diagnostics and the appropriate use of noninvasive tests (NITs). To learn more, listen to the full episode at https://t.co/fEM8gVX0uI. @RichmondVAMC

[Global Liver Institute @GlobalLiver]

We thank all the organizations joining us on International #NASHDay.

@Leberhilfe @EuropeLiver @EFSLNGO @LafiyaI @Leverpatienten @ANacionalMed @NASHNETglobal @liverUSA @Hepatos1 @Epatite

Link to #NASH day virtual panels: https://t.co/8Aysqp5uhA